Medical device company DexCom (NASDAQ:DXCM) in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company ...

The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative ...

DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong ...

DexCom Inc. closed 34.58% short of its 52-week high of $132.26, which the company reached on May 17th.

Below is Validea's guru fundamental report for DEXCOM INC (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of ...

Shares of DexCom Inc. DXCM shed 1.11% to $84.11 Tuesday, on what proved to be an all-around mixed trading session for the ...

The following seven stocks are all "strong buys" at five or more Wall Street firms, and have zero sell ratings at present.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...